Kunst was ousted from the Seattle-based Aurion after Swiss eye-care giant Alcon acquired a majority interest in the company ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired a majority interest in Aurion Biotech, Inc., a clinical-stage company ...

Spectacle lenses dominate Japan's myopia control market through cultural trust and accessibility, while multifocal and soft contact lenses gain tract ...

The global implantable collamer lens market is set to experience remarkable expansion in the coming decade, driven by the increasing adoption of minimally invasive vision correction procedures. Market ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional therapies ...

Mizuho raised the firm’s price target on Alcon (ALC) to $120 from $115 and keeps an Outperform rating on the shares following the capital ...

Please provide your email address to receive an email when new articles are posted on . Aurion will operate as a separate company. The Aurion board appointed Arnaud Lacoste, PhD, as CEO.

Cell therapy is emerging as a cutting-edge precision treatment in ophthalmology and is gaining immense popularity worldwide among people affected by degenerative eye diseases. Traditional ...

Impax Global Opportunities Fund underperformed the benchmark during the last quarter. Its overweight position in Health Care ...